Sign inJoin waitlistJoin the waitlist

JA

Jacob Appelbaum

Physician · University of Washington School of Medicine

Credentials: · · · · ·

History

University of Washington School of Medicine
2020–Present

Hematology
University of Washington School of Medicine
2016–2019
Internal Medicine
University of California-San Francisco
2013–2016
Yale School of Medicine
2009–2013

Research

Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival
Immunity · 2004 · 387 citations
Arginine topology controls escape of minimally cationic proteins from early endosomes to the cytoplasm
Chemistry & Biology · 2012 · First of 6 authors · 145 citations
Selective recognition of protein tetraserine motifs with a cell-permeable, pro-fluorescent bis-boronic acid
Journal of the American Chemical Society · 2009 · 126 citations

Roland Walter
13 papers
Anna Halpern
12 papers
Mary-Elizabeth Percival
12 papers
PH
Paul Hendrie
10 papers
EE
Elihu Estey
9 papers
Bart Scott
4 papers
Cristina Ghiuzeli
4 papers
Frederick Appelbaum
4 papers
Ryan Cassaday
4 papers
Blossom Raychaudhuri
3 papers · 3 as a fellow
Guillermo Garcia-Manero
3 papers
Harry Erba
3 papers

Grants

A Novel Small-Molecule Approach to Detect Specifc Peptide-MHC Complexes
National Heart, Lung, and Blood Institute · F30
Contact PI · $126.2K · Yale University
2008–2011

Clinical trials

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Principal investigator · Recruiting
Fred Hutchinson Cancer Center
2026–2029
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Principal investigator · Active not recruiting · Phase 1
Fred Hutchinson Cancer Center
2023–2029
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029